On MAY 27,2014 Novogen Limited (NASDAQ:NVGN, ASX:NRT), an oncology drug development company, announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers. Novogen Limited (ADR) (NASDAQ:NVGN) net profit margin is 18.80% and weekly performance is 4.05%. On last trading day company shares ended up $3.85. Novogen Limited (ADR) (NASDAQ:NVGN) distance from 50-day simple moving average is -0.99%.
Biotechnology Company, Retrophin Inc. (NASDAQ:RTRX) shares are up in the market by 25.47% after the company announced it had signed a binding commitment on a senior secured term loan facility, valued at $40 million. The term loan provided by Athyrium Capital Management is expected to Mature in 2018 with a LIBOR plus interest rate of 10%. Retrophin Inc (NASDAQ:RTRX) shares advanced 8.32% in last trading session and ended the day on $11.20. RTRX its return on assets is -310.50%. Retrophin Inc (NASDAQ:RTRX) quarterly performance is -43.46%.
Ventrus Biosciences, Inc. (Nasdaq:VTUS) announced that it has filed definitive proxy materials with the Securities and Exchange Commission (SEC) in connection with the upcoming annual meeting of Ventrus stockholders. The Company also announced that it is commencing the mailing of the definitive proxy materials to its stockholders. Ventrus Biosciences Inc (NASDAQ:VTUS) shares moved up 1.49% in last trading session and was closed at $1.36, while trading in range of $1.29-$1.42. Ventrus Biosciences Inc (NASDAQ:VTUS) year to date performance is -64.40%.
TherapeuticsMD, Inc. (NYSE MKT:TXMD) a women’s health care company, (“TherapeuticsMD” or the “Company”) announced that it will webcast its upcoming Investor Day on June 16, 2014 to be held at the InterContinental Barclay New York in New York City commencing promptly at 11:30 a.m. EDT to approximately 2:30 p.m. TherapeuticsMD Inc (NYSEMKT:TXMD) ended the last trading day at $4.36. Company weekly volatility is calculated as 6.15% and price to cash ratio as 13.97. TherapeuticsMD Inc (NYSEMKT:TXMD) showed a positive weekly performance of 11.79%.
KaloBios Pharmaceuticals, Inc. (NASDAQ:KBIO) will present at the Jefferies 2014 Global Healthcare Conference in New York City, NY. The event is scheduled to begin at 4:30 PM ET, June 3, 2014.KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) weekly performance is 6.18%. On last trading day company shares ended up $1.89.Analysts mean target price for the company is $7.50. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) distance from 50-day simple moving average is -12.98%.